Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-10-23
2008-08-12
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S543000, C514S678000
Reexamination Certificate
active
07410983
ABSTRACT:
The present invention relates to a combination of a peroxisome proliferator activated receptor (PPAR) activator and a benzoquinone and their use in treating and/or preventing disorders characterized by endothelial dysfunction, such as cardiovascular disease, strokes and myocardial infarction. According to a preferred embodiment of the invention the benzoquinone or precursor thereof is a ubiquinone or precursor thereof, more preferably, coenzyme Q10or a precursor thereof, and the PPAR activator is a fibrate or a thiazolidinedione, more preferably fenofibrate.
REFERENCES:
patent: 5229385 (1993-07-01), Terao et al.
patent: 5880148 (1999-03-01), Edgar et al.
patent: 6028109 (2000-02-01), Willson
patent: 6423742 (2002-07-01), Larson
patent: 614577 (1989-08-01), None
patent: 0 419 905 (1991-04-01), None
patent: 1 034 791 (2000-09-01), None
patent: WO 97/28149 (1999-08-01), None
Stedman's Medical Dictionary, 25th Edition, published 1990 by Williams & Wilkins (MD), P. 79, “angina”.
The Merck Manual of Diagnosis and Therapy, 14th Edition, published 1982 by Merck Sharpe & Dohme Research Laboratories, (NJ), pp. 494-511.
Belichard et al. “Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster”.Biochimica et Biophsical Acta, vol. 1169, pp. 98-102 (1993).
Anderson TJ, Uehata A, Gerhard MD, et al. “Close relationship of endothelial function in the human coronary and peripheral Circulation”.J Am Coll Cardiol, vol. 26, No. 1, pp. 235-241 (1995).
Cohen. “Dysfunction of vascular endothelium in diabetes mellitus”.Circulation, vol. 97, Suppl V, pp. V67-V76 (1993).
Issemann et al. “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators”.Nature, vol. 347, pp.645-650 (1990).
Furchgottet al. “The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine”.Nature, vol. 299, pp. 373-376 (1980).
Garg et al. “Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells”.J. Clin Invest, vol. 83, pp. 1774-1777 (1989).
Keller et al. “Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers”.Proc. Natl. Acad. Sci USA., vol. 90, pp. 2160-2164 (1993).
Moncada et al. “Nitric oxide: physiology, pathophysiology, and pharmacology”.Pharmacol.Rev, vol. 43, No. 2, pp. 109-142 (1991).
Radomski et al. “Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium”.Lancetvol. 2, pp. 1057:1058 (1987).
Rubanyi. “The role of endothelium in cardiovascular homeostasis and diseases”.J Cardiol Pharmacol vol. 22, Ssuppl 4, pp. 51-514 (1993).
Sax et al. “Impaired forearm vasodilator reseve in patients with microvascular angina. Evidence of a generalized disorder of vascular function?”.New England Journal of Medicine, vol. 317, pp. 1366-1370 (1987).
Schachinger et al. “Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease”.Circulation, vol. 101, pp. 1899-1906 (2000).
Suwaidi et al. “Long term follow-up of patients with mild coronary artery disease and endothelial dysfunction”.Circulation, vol. 101, pp. 948-954 (2000).
Watts et al. “Dyslipoproteinemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis”.Atherosclerosis, vol. 141, pp. 17-30 (1998).
Widlansky et al., “The Clinical Implications of ENdothelial Dysfunctionn,”,J. Am. Coll. Cardiol., 2003; 42:1149-60.
Modena et al., “Prognostic Role of Reversible Endothelial Dysfunction in Hypertensive Postmenopausal Women,”J. Am. Coll. Cardiol., 2002; 40:505-10.
Playford David Alan
Watts Gerald Francis
Fournier Laboratories Ireland Limited
Henley, III Raymond J
Merchant & Gould P.C.
LandOfFree
Combination of fenofibrate and coenzyme q10 for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of fenofibrate and coenzyme q10 for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of fenofibrate and coenzyme q10 for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4016119